Aspirin resistance in cardiovascular disease: Pathogenesis, diagnosis and clinical impact

Current Pharmaceutical Design

Volumn 15, Issue 10, 2009, Pages 1085-1094

  Papathanasiou, Athanasios ^a   Guodevenos, John ^a   Tselepis, Alexandros D ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Acetylsalicylic acid; Antiplatelet medication; Aspirin; Platelets; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PICOTAMIDE; PIROXICAM; PLACEBO; ROFECOXIB; STEROID; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ACUTE HEART INFARCTION; ARTERITIS; ARTERY DISEASE; ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE RESISTANCE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENDOCARDITIS; HEART FAILURE; HUMAN; IN VITRO STUDY; ISCHEMIA; LABORATORY TEST; LOW DRUG DOSE; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; ANIMALS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION;

EID: 65649133054     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846964     Document Type: Review

References (122)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8(11): 1227-34.
2. Marutsuka K, Hatakeyama K, Yamashita A, Asada Y. Role of thrombogenic factors in the development of atherosclerosis. J Atheroscler Thromb 2005; 12(1): 1-8.
3. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359(9): 938-49.
4. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006; 107(10): 3902-6.
5. Mangin P, Yap CL, Nonne C, Sturgeon SA, Goncalves I, Yuan Y, et al. Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. Blood 2006; 107(11): 4346-53.
6. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004; 2(4): 535-45.
7. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1(7): 1602-12.
8. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94(6): 1226-32.
9. Roque M, Reis ED, Fuster V, Padurean A, Fallon JT, Taubman MB, et al. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Am Coll Cardiol 2000; 36(7): 2303-10.
10. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197(11): 1585-98.
11. Born GV. Platelets in thrombogenesis: mechanism and inhibition of platelet aggregation. Ann R Coll Surg Engl 1965; 36: 200-6.
12. Du X, Gu M, Weisel JW, Nagaswami C, Bennett JS, Bowditch R, et al. Long range propagation of conformational changes in integrin alpha IIb beta 3. J Biol Chem 1993; 268(31): 23087-92.
13. Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000; 105(6): 699-701.
14. Michelson AD, platelets. 2006, San Diego CA: Elsevier/Academic Press.
15. Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets 2000; 11(1): 28-32.
16. Holmsen H. Platelet metabolism and activation. Semin Hematol 1985; 22(3): 219-40.
17. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99(12): 1293-304.
18. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56(3): 624-32.
19. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101(10): 1206-18.
20. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330(18): 1287-94.
21. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353(22): 2373-83.
22. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311(19): 1206-11.
23. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 234S-64S.
24. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
25. Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308(14): 800-5.
26. Lordkipanidze M, Pharand C, Palisaitis DA, Diodati JG. Aspirin resistance: truth or dare. Pharmacol Ther 2006; 112(3): 733-43.
27. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25(2): 166-81.
28. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, et al. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002; 20(5): 1015-22.
29. Papathanasiou AI, Goudevenos JA, Mikhailidis DP, Tselepis AD. Acute and long-term antiplatelet therapy. Drugs Today (Barc) 2008; 44(5): 331-52.
30. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100(9): 1016-30.
31. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2003; 24(1): 28-66.
32. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 576S-99S.
33. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, et al. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 2005; 16(2): 65-71.
34. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004; 15(2): 117-25.
35. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88(6): 787-800.
36. Smout JD, Mikhailidis DP, Shenton BK, Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost 2004; 10(1): 9-18.
37. Collins TC, Souchek J, Beyth RJ. Benefits of antithrombotic therapy after infrainguinal bypass grafting: a meta-analysis. Am J Med 2004; 117(2): 93-9.
38. CURE, Trial, Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without St-segment elevation. N Engl J Med 2001; 345: 494-502.
39. COMMIT, Collabarative, Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-21.
40. Sabatine MS, Cannon CP, Gibson M, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
41. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004; 164(19): 2106-10.
42. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294(10): 1224-32.
43. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., Jacobs AK, Kern MJ, King SB, 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113(7): e166-286
44. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121(1): 43-9.
45. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
46. Kjeldsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens 2000; 18(5): 629-42.
47. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26(12): 3264-72.
48. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295(3): 306-13.
49. Deliargyris EN, Boudoulas H. Aspirin resistance. Hellenic J Cardiol 2004; 45: 1-5.
50. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367(9510): 606-17.
51. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46(6): 986-93.
52. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88(5): 711-5.
53. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71(5): 397-403.
54. Bhatt DL, Topol EJ. Scientific and therapeutic advances in anti-platelet therapy. Nat Rev Drug Discov 2003; 2(1): 15-28.
55. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110(19): e489-93.
56. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50(19): 1822-34.
57. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4(2): 312-9.
58. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88(3): 230-5.
59. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36(5): 1001-5.
60. Michelson AD, Frelinger AL, 3rd, Furman MI. Current options in platelet function testing. Am J Cardiol 2006; 98(10A): 4N-10N.
61. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115(25): 3156-64.
62. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153(2): 175-81.
63. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51(19): 1829-43.
64. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41(6): 961-5.
65. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336(7637): 195-8.
66. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167(15): 1593-9.
67. Madsen EH, Schmidt EB, Maurer-Spurej E, Kristensen SR. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 2008; 19(5): 335-41.
68. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105(14): 1650-5.
69. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118(7): 723-7.
70. Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003; 92(12): 1492-4.
71. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107(1-2): 45-9.
72. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95(8): 973-5.
73. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27(22): 2667-74.
74. Frelinger AL, 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113(25): 2888-96.
75. Catella-Lawson F, Reily MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
76. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99(11): 7634-9.
77. Bates ER, Lau WC. Controversies in antiplatelet therapy for patients with cardiovascular disease. Circulation 2005; 111(17): e267-71.
78. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360(9339): 1071-3.
79. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351(17): 1709-11.
80. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553): 1302-8.
81. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296(13): 1633-44.
82. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113(25): 2906-13.
83. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364(9435): 675-84.
84. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115(12): 1634-42.
85. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50(7): el-e157.
86. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117(2): 296-329.
87. Dotsenko O, Kakkar VV. Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. J Thromb Haemost 2007; 5(2): 224-31.
88. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006; 8(4): 428-32.
89. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148(1): 157-64.
90. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31(2): 419-25.
91. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997; 79(7): 909-13.
92. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355(9215): 1575-81.
93. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79(2): 115-9.
94. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327(10): 685-91.
95. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325(5): 293-302.
96. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336(4): 251-7.
97. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342(8875): 821-8.
98. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354(9172): 9-12.
99. Leor J, Reicher-Reiss H, Goldbourt U, Boyko V, Gottlieb S, Battler A, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33(7): 1920-5.
100. Echemann M, Alla F, Briancon S, Juilliere Y, Virion JM, Mertes PM, et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart Fail 2002; 4(5): 647-54.
101. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29(19): 2388-442.
102. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004; 10(2): 101-12.
103. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6(4): 501-8.
104. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10(4): S1-S10.
105. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113(19): 2363-72.
106. Gerotziafas G, Vasilopoulos D, Vemmos K, Katsamouris K, Mikchailidis D, Tselepis A, et al. Guidelines for antiplatelet treatment in patients with atherothrombosis or patients with risk of atherothrombosis. Hellenic J Cardiol 2006; 47 (SupplA): 7-48.
107. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM. Results of the BRAT study - a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000; 16(11): 1385-90.
108. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52(9): 734-9.
109. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4(3): 542-9.
110. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46(10): 1820-6.
111. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol 2006; 19(5): 439-48.
112. Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 2003; 25(1): 16-22.
113. Reininger CB, Boeger CA, Steckmeier B, Spannagl M, Scweiberer L. Mechanisms underlying increased platelet reactivity in patients with peripheral arterial disease. Preliminary results. Int Angiol 1999; 18(2): 163-70.
114. Reininger CB, Greinacher A, Graf J, Lasser R, Steckmeier B, Schweiberer L. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 1996; 81(6): 641-9.
115. Walters TK, Mitchell DC, Wood RF. Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg 1993; 80(10): 1266-8.
116. Barradas MA, Stansby G, Hamilton G, Mikhailidis DP. Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol 1994; 13(3): 202-7.
117. Muir AR, Patterson C, McMullin MF, McKeown PP. Assessment of Aspirin Resistance Varies on a Temporal Basis in Patients with Ischaemic Heart Disease. Heart 2008; [Epub ahead of print].
118. Modesti PA, Cecioni I, Colella A, Costoli A, Paniccia R, Neri Serneri GG. Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist. Br J Pharmacol 1994; 112(1): 81-6.
119. Neri Serneri GG, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25(20): 1845-52.
120. Asanuma M, Miyazaki I. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. Curr Pharm Des 2008; 14(14): 1428-34.
121. Barantke M, Bonnemeier H. Factor Xa inactivation in acute coronary syndrome. Curr Pharm Des 2008; 14(12): 1186-90.
122. Hartmann F. Safety and efficacy of bivalirudin in acute coronary syndromes. Curr Pharm Des 2008; 14(12): 1191-6.